Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga. The injected treatment, which will carry the commercial name Lerochol, is ...

LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line ...